Double-edged sword: intranasal ketamine reduces opioid needs in cancer pain, highlighting concerns over adverse effects.
Intranasal ketamine may reduce opioid requirements in cancer-related pain, but adverse effects can limit tolerability. Future research should identify high-risk patients and develop risk mitigation strategies.
No takes yet. Share an insight, caveat, or question.
Nalbone et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: